SecBot SecBot

ZLAB

Zai Lab Ltd
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001704292 Biotech & Drug Discovery
$23.47 −1.13 (−4.59%)
Nov 16 4:00 PM ET · prev $24.60
Market cap
$2.9B
Mid cap
Median target
$34.75
+48% · range $24.25–56.00
1 year
+12.2%
from $20.92 · Nov 17
30 days
−2.5%
from $24.06
52-week range
$16.30–27.00
−13% from high · low Feb 2
Avg volume 20D
1.33M
Oct 23 spike 3.69M
Short interest
8.09M
≈7.2% of shares · −8.5%
Days to cover
6.7
at average volume
Insider net
−$5.1M
1 buyer · 4 sellers · since Apr 6
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
23
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next FDA decision date, Nov 30, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $66.5K at an average $22.42. 4 insiders sold $5.2M.

  • InstitutionsMIXED

    Q3 2026: 16 added (1 new), 13 trimmed or exited.

  • Short sellersSTEADY

    Short interest −8.5% to 8.09M shares. 6.7 days to cover, ≈7.2% of shares.

  • TrendRANGE

    4% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
FMR LLCTRIM1,070,740$28.2M
Aberdeen Group plcTRIM155,547$4.1M
ALPS ADVISORS INCADD148,993$3.9M
Quadrature Capital LtdDOUBLED88,632$2.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED57,946$1.5M
MARSHALL WACE, LLPTRIM37,809$995.9K
UBS Group AGTRIM35,123$925.1K
Invesco Ltd.ADD31,250$823.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 12 analysts

Price is below the lowest target. Median implies +48%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 7, 2026Citigroup
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$66.5K
bought · 1 insider
$5.2M
sold · 4 insiders
+4.7%
vs their $22.42 cost
DateInsiderTypeValue
Nov 10, 2026
GAYNOR RICHARD
Director
Nov 10, 2026
BUY$33.4K
Oct 1, 2026
Chen Yajing
Chief Financial Officer
Oct 1, 2026
TAX W/H$8.0K
Oct 1, 2026
Chen Yajing
Chief Financial Officer
Oct 1, 2026
EXERCISE920 sh
Aug 19, 2026
Chen Yajing
Chief Financial Officer
Aug 19, 2026
SELL$7.0K
Aug 14, 2026
Chen Yajing
Chief Financial Officer
Aug 14, 2026
EXERCISE1,250 sh
Aug 14, 2026
Chen Yajing
Chief Financial Officer
Aug 14, 2026
TAX W/H$11.1K
Aug 12, 2026
Lis William
Director
Aug 12, 2026
SELL$212.7K
Aug 11, 2026
Chen Yajing
Chief Financial Officer
Aug 11, 2026
SELL$15.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.43-$0.47–-$0.40+17.9%$112.9M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
8,092,682
shares short
-8.5%
vs prior settlement
6.7
days to cover
≈7.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 10, 2026 Insider
GAYNOR RICHARD bought 1,228 shares
Director @ $27.19 ($33.4K)
Nov 5, 2026 SEC
Zai Lab reported Q3 2026 total revenue of $108.2M, down 7% YoY from $116.1M, and a GAAP net loss of $46.1M ($0.41 per…
8-K · Impact 5/10
Oct 23, 2026 SEC
Zai Lab announced a $250M PIPE financing, selling 11.34M ADSs at $22.04/ADS to a syndicate of healthcare-focused…
8-K · Impact 6/10
Oct 15, 2026 Short interest report
Short Interest: ZLAB up 24% to 8.8M shares
Settlement 2026-10-15 | Days to cover: 11.28 | ≈7.88% of shares outstanding (est.)
Oct 1, 2026 Insider
Chen Yajing surrendered for taxes 315 shares
Chief Financial Officer @ $25.50 ($8.0K)
Oct 1, 2026 Insider
Chen Yajing acquired via exercise 920 shares
Chief Financial Officer
Sep 30, 2026 Inst.
FMR LLC · TRIM
1,070,740 shares ($28.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

23 filings · 2 bullish · 5 bearish · 16 neutral
All ZLAB filing & press-release reports (23)